LIAN vs. EVAX, PHXM, AFMD, FGEN, OMGA, KNTE, NGM, GSDI, ACXP, and BCTX
Should you be buying LianBio stock or one of its competitors? The main competitors of LianBio include Evaxion Biotech A/S (EVAX), PHAXIAM Therapeutics (PHXM), Affimed (AFMD), FibroGen (FGEN), Omega Therapeutics (OMGA), Kinnate Biopharma (KNTE), NGM Biopharmaceuticals (NGM), Global System Dynamics (GSDI), Acurx Pharmaceuticals (ACXP), and BriaCell Therapeutics (BCTX). These companies are all part of the "medical" sector.
LianBio (NASDAQ:LIAN) and Evaxion Biotech A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and community ranking.
Evaxion Biotech A/S received 13 more outperform votes than LianBio when rated by MarketBeat users. Likewise, 56.67% of users gave Evaxion Biotech A/S an outperform vote while only 36.36% of users gave LianBio an outperform vote.
LianBio has a beta of 0.23, meaning that its stock price is 77% less volatile than the S&P 500. Comparatively, Evaxion Biotech A/S has a beta of -0.22, meaning that its stock price is 122% less volatile than the S&P 500.
In the previous week, Evaxion Biotech A/S had 1 more articles in the media than LianBio. MarketBeat recorded 1 mentions for Evaxion Biotech A/S and 0 mentions for LianBio. Evaxion Biotech A/S's average media sentiment score of 0.67 beat LianBio's score of 0.00 indicating that Evaxion Biotech A/S is being referred to more favorably in the news media.
74.8% of LianBio shares are owned by institutional investors. Comparatively, 11.0% of Evaxion Biotech A/S shares are owned by institutional investors. 7.6% of LianBio shares are owned by insiders. Comparatively, 41.6% of Evaxion Biotech A/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Evaxion Biotech A/S has higher revenue and earnings than LianBio. Evaxion Biotech A/S is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.
LianBio's return on equity of -33.17% beat Evaxion Biotech A/S's return on equity.
LianBio presently has a consensus target price of $5.33, indicating a potential upside of 1,593.12%. Evaxion Biotech A/S has a consensus target price of $11.00, indicating a potential upside of 181.33%. Given LianBio's higher probable upside, equities research analysts plainly believe LianBio is more favorable than Evaxion Biotech A/S.
Summary
Evaxion Biotech A/S beats LianBio on 9 of the 16 factors compared between the two stocks.
Get LianBio News Delivered to You Automatically
Sign up to receive the latest news and ratings for LIAN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LIAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
